Evolus Inc (EVL F) stock market data APIs
€13.7767
0(0%)
as of February 17, 2025
Evolus Inc Financial Data Overview
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Prev. Close
13.7767
Open
13.7767
High
13.7767
Low
13.7767
52 wk Range
9.1-15.9
Market Cap
880 M
Shares Outstanding
63 322 K
Revenue
248 M
EPS
-0.19
Beta
1.333
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evolus Inc data using free add-ons & libraries
Get Evolus Inc Fundamental Data
Evolus Inc Fundamental data includes:
- Net Revenue: 248 M
- EBITDA: -26 272 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-04
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evolus Inc News
New
Evolus Insider Ups Holding By 210% During Year
Insiders were net buyers of Evolus, Inc.'s (NASDAQ:EOLS ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important thing w...
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
Preliminary Unaudited Net Revenue of Approximately $61 Million for the Fourth Quarter 2023, Representing 40% Growth Over the Prior Year Quarter and a 22% Increase Over the Prior Sequential Quarter Pr...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif., January 12, 2024--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported t...
Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?
Evolus, Inc. (EOLS) closed the last trading session at $10.37, gaining 8.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Stre...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
